Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
Biodesix, Inc. (BDSX)
Company Research
Source: GlobeNewswire
Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentations on lung cancer diagnostics and new research on breast cancer diagnostics at upcoming scientific meetings. At the 2025 North American Conference on Lung Cancer (NACLC), December 5 - 7, in Chicago, IL, Biodesix will present new findings on its on-market Nodify Lung® tests, with data that spotlight the importance of timely, accurate lung nodule risk classification to support the early detection of lung cancer: Refining Post-test Probability of Lung Cancer Using Post-Market Data from a Bloo
Show less
Read more
Impact Snapshot
Event Time:
BDSX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDSX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDSX alerts
High impacting Biodesix, Inc. news events
Weekly update
A roundup of the hottest topics
BDSX
News
- Biodesix (NASDAQ:BDSX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Biodesix (NASDAQ:BDSX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Biodesix (NASDAQ:BDSX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=BDSX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> fMarketBeat
- Biodesix Announces Third Quarter 2025 Results and HighlightsGlobeNewswire
- Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual MeetingGlobeNewswire
BDSX
Earnings
- 11/3/25 - Beat
BDSX
Analyst Actions
- 9/19/25 - Canaccord Genuity
BDSX
Sec Filings
- 11/3/25 - Form 10-Q
- 11/3/25 - Form 8-K
- 10/2/25 - Form 4
- BDSX's page on the SEC website